In a next step, cut-off values of all significantly dysregulated cytokines/chemokines were calculated to discriminate MOGAD and AQP4+ NMOSD from MS patients with 90% specificity (Supplementary Table 1). This evidence concerns the gene AQP4 and myeloid sarcoma.